(lp0
S'Latest Stocks: The Curis, Inc.  Earns Buy Rating from Cowen and Company Petro Global News 24 - 8 hours ago Cowen and Company reaffirmed their buy rating on shares of Curis, Inc.  in a research note published on Wednesday.Curis, Inc.  to Release Earnings on Thursday - The Cerbat GemCuris, Inc.  Announces Earnings Results - Community Financial News'
p1
aS"Analysts Near-Term outlook: The Medicines Company , Curis, Inc.  The USA Commerce - Mar 27, 2017 Shares of The Medicines Company  surged 1.40% to $50.69. During the trading on 03/24/2017, Company's stock ranged from $50.94 to $49.69."
p2
aS"Curis: One Swallow Doesn't Make A Summer Seeking Alpha - Nov 22, 2016 Curis Therapeutics   was incorporated on February 14, 2000 and trades on the Nasdaq Global Market. Headquartered in Lexington, Massachusetts, it is a clinical-stage biopharmaceutical company engaged in developing and&nbsp;..."
p3
aS'PT Review for Curis, Inc.  Aiken Advocate - 17 hours ago Using data provided from various analysts, shares of Curis, Inc.  are presently listed with an ABR of 1. This number is using a recommendation scale where the ratings range from a 1 to a 5. Following this scale, a 1 would signify a Strong ...'
p4
aS'Curis Inc.  Plunges 6.04% on March 21 Equities.com - Mar 21, 2017 Curis Inc.  had a rough trading day for Tuesday March 21 as shares tumbled 6.04%, or a loss of $-0.18 per share, to close at $2.80.Curis, Inc.  Position Reduced by Fmr LLC - BNB Daily '
p5
aS"Buy or Sell? Average Brokerage Ratings on Curis, Inc. , Webster ... StockNewsJournal - Mar 27, 2017 Investors who are keeping close eye on the stock of Curis, Inc.  established that the company was able to keep return on investment at -94.09 in the trailing twelve month while Reuters data showed that industry's average stands at -2.56 ..."
p6
aS'Curis, Inc.  Could Reverse On Near Term Catalysts Insider Financial - Jul 22, 2016 Massachusetts based biotech Curis, Inc.  soared into the close of 2015, as data from its lead oncology candidate hinted at a revolution in cancer therapy.'
p7
aS'Curis to Present at the Oppenheimer &amp; Co. Inc. 27th Annual Healthcare Conference GlobeNewswire  - Mar 16, 2017 LEXINGTON, Mass., March 16, 2017  -- March 16, 2017 - Curis, Inc. , a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today&nbsp;...'
p8
aS'Stock Update : Curis, Inc. and Aurigene Extend Exclusivity Period ... Smarter Analyst - Jan 9, 2017 Curis, Inc.  announced that it has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015.'
p9
aS'Curis Inc.  Moves Higher on Volume Spike for March 24 Equities.com - Mar 24, 2017 Curis Inc.  traded on unusually high volume on Mar. 24, as the stock gained 3.5% to close at $2.96. On the day, Curis Inc. saw 1.13 million shares trade hands on 3,369 trades. Considering that the stock averages only a daily volume of 642,412 ...Latest Stocks: Curis, Inc.  Downgraded by Zacks Investment Research to Hold - Petro Global News 24Cowen and Company Reiterates Buy Rating for Curis, Inc.  - Sports Perspectives'
p10
a.